Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials

SIMPLE SUMMARY: Neurotoxicity is an on-target side effect of GD2-directed immunotherapy due to the expression of GD2 on healthy cells. Patients with high-risk neuroblastoma who receive treatment with anti-GD2 immunotherapy, therefore, require close observation and supportive management to improve tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wieczorek, Aleksandra, Manzitti, Carla, Garaventa, Alberto, Gray, Juliet, Papadakis, Vassilios, Valteau-Couanet, Dominique, Zachwieja, Katarzyna, Poetschger, Ulrike, Pribill, Ingrid, Fiedler, Stefan, Ladenstein, Ruth, Lode, Holger N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026788/
https://www.ncbi.nlm.nih.gov/pubmed/35454826
http://dx.doi.org/10.3390/cancers14081919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026788/
https://www.ncbi.nlm.nih.gov/pubmed/35454826
http://dx.doi.org/10.3390/cancers14081919

Ejemplares similares